Your browser doesn't support javascript.
loading
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.
Lenhard, Justin R; Bulitta, Jürgen B; Connell, Terry D; King-Lyons, Natalie; Landersdorfer, Cornelia B; Cheah, Soon-Ee; Thamlikitkul, Visanu; Shin, Beom Soo; Rao, Gauri; Holden, Patricia N; Walsh, Thomas J; Forrest, Alan; Nation, Roger L; Li, Jian; Tsuji, Brian T.
Afiliação
  • Lenhard JR; Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA.
  • Bulitta JB; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Connell TD; California Northstate College of Pharmacy, Elk Grove, CA, USA.
  • King-Lyons N; Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA.
  • Landersdorfer CB; Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Cheah SE; Department of Microbiology and Immunology and The Witebsky Center for Microbial Pathogenesis and Immunology, University at Buffalo, State University of New York, Buffalo, NY, USA.
  • Thamlikitkul V; Department of Microbiology and Immunology and The Witebsky Center for Microbial Pathogenesis and Immunology, University at Buffalo, State University of New York, Buffalo, NY, USA.
  • Shin BS; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Rao G; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Holden PN; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Walsh TJ; Catholic University of Daegu, Hayang, South Korea.
  • Forrest A; Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA.
  • Nation RL; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Li J; Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA.
  • Tsuji BT; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
J Antimicrob Chemother ; 72(1): 153-165, 2017 01.
Article em En | MEDLINE | ID: mdl-27634916
ABSTRACT

OBJECTIVES:

The pharmacodynamics of polymyxin/carbapenem combinations against carbapenem-resistant Acinetobacter baumannii (CRAB) are largely unknown. Our objective was to determine whether intensified meropenem regimens in combination with polymyxin B enhance killing and resistance suppression of CRAB.

METHODS:

Time-kill experiments for meropenem and polymyxin B combinations were conducted against three polymyxin B-susceptible (MIC of polymyxin B = 0.5 mg/L) CRAB strains with varying meropenem MICs (ATCC 19606, N16870 and 03-149-1; MIC of meropenem = 4, 16 and 64 mg/L, respectively) at 108 cfu/mL. A hollow-fibre infection model was then used to simulate humanized regimens of polymyxin B and meropenem (2, 4, 6 and 8 g prolonged infusions every 8 h) versus N16870 at 108 cfu/mL over 14 days. New mathematical mechanism-based models were developed using S-ADAPT.

RESULTS:

Time-kill experiments were well described by the mathematical mechanism-based models, with the presence of polymyxin B drastically decreasing the meropenem concentration needed for half-maximal activity against meropenem-resistant populations from 438 to 82.1 (ATCC 19606), 158 to 93.6 (N16870) and 433 to 76.0 mg/L (03-149-1). The maximum killing effect of combination treatment was similar among all three strains despite divergent meropenem MIC values (Emax = 2.13, 2.08 and 2.15; MIC of meropenem = 4, 16 and 64 mg/L, respectively). Escalating the dose of meropenem in hollow-fibre combination regimens from 2 g every 8 h to 8 g every 8 h resulted in killing that progressed from a >2.5 log10 cfu/mL reduction with regrowth by 72 h (2 g every 8 h) to complete eradication by 336 h (8 g every 8 h).

CONCLUSION:

Intensified meropenem dosing in combination with polymyxin B may offer a unique strategy to kill CRAB irrespective of the meropenem MIC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimixina B / Tienamicinas / Resistência beta-Lactâmica / Acinetobacter baumannii / Antibacterianos Limite: Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimixina B / Tienamicinas / Resistência beta-Lactâmica / Acinetobacter baumannii / Antibacterianos Limite: Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos